The pharmaceutical company Pfizer said Wednesday that the latest data from its coronavirus vaccine stage three trials shows it to be 95% effective, which would mean the vaccine is even better than the original announcement from earlier this month.
According to Pfizer, the primary efficacy analysis from the vaccine trials shows that the vaccine is around 95% effective against COVID-19 beginning one month after the first dose (the vaccine requires two doses, spaced three weeks apart). When the interim efficacy analysis data results were announced on November 9, the pharmaceutical company indicated that the vaccine was roughly 90% effective at preventing COVID-19.
“The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic,” said Dr. Albert Bourla, the CEO and chairman of Pfizer. “We continue to move at the speed of science to compile all the data collected thus far and share with regulators around